Source - Alliance News

Arecor Therapeutics PLC on Monday said it has expanded its hospital formulation collaboration with the pharmaceutical division of an unnamed partner.

The West Sussex, England-based commercial biotechnology company said the partnership, in which it is using its proprietary formulation technology platform, Arestat, to develop a liquid formulation of its partner’s product, AT351, has progressed significantly since it began in November 2022.

Arecor will now carry out additional activities to accelerate the development programme ahead of its partner’s pre-investigational new drug meeting with the US Food & Drug Administration.

Chief Executive Officer Sarah Howell said: ‘The rapid progress of this collaboration and expansion of the development project illustrate the value that our proprietary technology platform, Arestat, and our experience in the specialty hospital field, can bring to our partners and the development of differentiated medicines to improve patient outcomes.’

Shares in Arecor were up 0.6% at 175.00 pence each in London on Monday morning.

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Arecor Therapeutics PLC (AREC)

0p (0.00%)
delayed 15:57PM